Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

2019-06-10
Price :
Published : Jun-2019
No. of Pages : 79
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Increasing Global Burden of Allergic Diseases Accentuates Need for Novel Treatments
2.2 Small but Innovative Pipeline Holds Potential for Breakthrough Treatment Approaches
2.3 Interleukin-Targeting Monoclonal Antibodies Attract High Deal Values
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
4.3 Sustained Innovation in Allergic Diseases
4.4 Epidemiology for Allergic Diseases
4.5 Overview for Marketed Products
5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs Between Allergic Diseases Market and Pipeline by Therapeutic Target Family
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Target Within the Pipeline
6 First-in-Class Molecular Target Evaluation
6.1 Overview
6.2 Pipeline Programs Targeting Toll-Like Receptor 8 for Allergic Rhinitis
6.3 Pipeline Programs Targeting Cholesterol Side Chain Cleavage Enzyme Mitochondrial for Peanut Allergy
6.4 Pipeline Programs Targeting Low Affinity Immunoglobulin Gamma Fc Region Receptor ii-b for Allergic Rhinitis, Allergic Asthma, Allergic Conjunctivitis, and Atopic Dermatitis
6.5 Pipeline Programs Targeting Signal Transducer and Activator of Transcription 6 for Allergic Asthma and Atopic Dermatitis
6.6 Pipeline Programs Targeting Cytokine Receptor Common Subunit Beta for Allergic Asthma
6.7 Pipeline Programs Targeting Eotaxin-1 for Allergic Conjunctivitis
6.8 Pipeline Programs Targeting Trans Acting T Cell Specific Transcription Factor GATA 3 for Atopic Dermatitis and Allergic Asthma
6.9 Pipeline Programs Targeting Interleukin-1 Receptor Accessory Protein for Atopic Dermatitis
7 Key Players and Deals
7.1 Overview
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.4 About the Authors
8.5 About GlobalData
8.6 Contact Us
8.7 Disclaimer

1.1 List of Tables
Table 1: Classification of Asthma by Severity
Table 2: Classification of Allergic Conjunctivitis
Table 3: Classification of Atopic Dermatitis Severity
Table 4: Allergic Rhinitis Total Prevalent Cases (millions), 2013-2023
Table 5: Asthma Lifetime Diagnosed Prevalent Cases (millions), 2013-2023
Table 6: Allergic Conjunctivitis Total Prevalent Cases (millions), 2013-2023
Table 7: Atopic Dermatitis Diagnosed Prevalent Cases (millions), 2017-2027
Table 8: Peanut Allergy Probable Diagnosed Prevalent Cases (millions), 2017-2027

1.2 List of Figures
Figure 1: Allergic Diseases, Global, Classification of Allergic Rhinitis, 2019
Figure 2: Allergic Diseases, Global, Differences Between Food Intolerance and Food Allergy, 2019
Figure 3: Allergic Diseases, Global Market by Molecule Type and Molecular Target, 2019
Figure 4: Allergic Diseases,, Global Pipeline, by Stage of Development and Molecule Type, 2019
Figure 5: Allergic Diseases Global Pipeline for Key Indications, by Stage of Development, 2019
Figure 6: Allergic Diseases Global Pipeline for Key Indications, by Molecule Type, 2019
Figure 7: Allergic Diseases Global Pipeline, by Molecular Target and Stage of Development, 2019
Figure 8: Allergic Diseases Global Pipeline for Key Indications, by Molecular Target, 2019
Figure 9: Allergic Diseases Global Distribution of Pipeline and Marketed Products, by Molecular Target Class, 2019
Figure 10: Allergic Diseases Global Distribution of Pipeline Products, by First-in-Class Status and Molecular Target Class, 2019
Figure 11: Allergic Diseases, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
Figure 12: Allergic Diseases Global Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets, by Stage of Development and Molecular Target Class, 2019
Filed in: Pharmaceutical
Publisher : GlobalData